My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 11 759 / https://doi.org/10.3332/ecancer.2017.759

Research

Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy

Introduction: In locally and locally advanced triple-negative breast cancer (TNBC), neoadjuvant chemotherapy (NAC) only induces a pCR in 30–35% of patients. Clinical and pathological factors are not enough to distinguish the patients who have no chance of a pCR or not. The tumour microenvironment is critical for cancer and tumour-infiltrating lymphocytes (TIL). Moreover, the NAC scenario is the perfect setting to study possible changes in TIL levels.

Material and methods: Using our prospective maintained breast cancer (BC) database, we identified 164 TNBC patients treated with NAC between 1998 and 2015 with enough samples of diagnostic biopsy and after surgery. Evaluation of TILs before and after NAC followed a standardised methodology for visual assessment on haematoxylin–eosin sections and the amounts of TILs were quantitated in deciles. We categorised lymphocyte-predominant breast cancer cutoff according to a receiver operating characteristic (ROC) analysis. We categorised LPBC as involving > 40% lymphocytic infiltration tumour stroma. The primary end point was predictive value of TILs to NAC, and the secondary end point was disease-free survival (DFS). DFS was analysed using the Kaplan–Meier method and the groups were compared with a long-rank test. Univariate and multivariate Cox models were used to generate hazard ratios for determining associations between variables such as TIL after NAC and DFS.

Results: A total of 164 TNBC patients were treated with NAC and surgery. The main patients’ characteristics are listed in Table 1. We identify different pathological complete response to anthracycline and taxane-based NAC; LPBC subgroup 51 from 58 patients (88%) pCR versus non- lymphocyte-predominant breast cancer (LPBC) subgroup 10 from 106 (9%) pCR, p = 0.001. At a median follow-up of 78 months, LPBC was associated with better DFS; the three-year Kaplan–Meier estimates for DFS were 2% and 30 % for patients with LPBC and non-LPBC, respectively, p = 0.01. Univariate and multivariate analysis confirmed TIL to be an independent prognostic marker of DFS.

Conclusions: Tumour-infiltrating lymphocytes could be routinely used in locally advanced TNBC treated with anthracycline and taxane, such as biomarker, to be enabled the identification of different two subgroups: LPBC patients have a very high response to NAC pCR 88%, meanwhile non-LPBC patients only achieve 9%. Moreover, non-LPBC patients have a worse prognosis than LPBC patients. This data verified the predictive and prognostic value of TIL.

Keywords: triple-negative breast cancer, tumour-infiltrating lymphocytes, predictive, prognostic value

Loading Article Metrics ... Please wait

Related articles

Research: Frozen section evaluation of sentinel lymph nodes in breast carcinoma: a retrospective analysis

Abstract | Full Article | PDF Published: 18 Oct 2017 / https://doi.org/10.3332/ecancer.2017.774

Research: A discrete transition zone between cuticle and cortex layers of a human hair fibre: changes observed in the presence of breast cancer

Abstract | Full Article | PDF Published: 13 Oct 2017 / https://doi.org/10.3332/ecancer.2017.772

Conference Report: Highlights from the WIN 2017 Symposium, 26–27 June 2017, Paris, France: ‘Expediting Global Innovation in Precision Cancer Medicine’

Abstract | Full Article | PDF Published: 27 Sep 2017 / https://doi.org/10.3332/ecancer.2017.770

Research: Limitations of workers diagnosed with cancer evaluated with Work Role Functioning Questionnaire-Br

Abstract | Full Article | PDF | Portuguese Published: 18 Sep 2017 / https://doi.org/10.3332/ecancer.2017.769

Review: Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer

Abstract | Full Article | PDF Published: 18 Sep 2017 / https://doi.org/10.3332/ecancer.2017.768



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence